**Table 1. Characteristics of the treated patients with HCV infection (n = 32)**

|  |  |  |
| --- | --- | --- |
| **Parameter** | **Patient numbers, n (%)** | **95% CI** |
| Age, years |
| 12–14 | 14 (43.75) | 26.36–62.34 |
| 15–17 | 18 (56.25) | 37.66–73.64 |
| Gender |
| Female | 16 (50) | 31.89–68.11 |
| Male | 16 (50) | 31.89–68.11 |
| Transmission type |
| Vertical, including perinatal contact with | 20 (62.5) | 43.7–78.9 |
| HCV | 16 (50) | 31.9–68.1 |
| HCV/HIV | 4 (12.5) | 3.5–29.0 |
| Medical procedures | 4 (12.5) | 3.1–29.0 |
| Unknown | 8 (25) | 11.5–43.4 |
| The region of transmission |
| Moscow region | 28 (87.5) | 71.0–96.5 |
| Other regions of the Russian Federation | 2 (6.25) | 0.77–20.8 |
| Neighboring countries | 2 (6.25) | 0.77–20.8 |
| Social factors |
| Social care residents/pupils | 1 (3.1) | 0.08–16.2 |
| Guardian-cared | 7 (21.9) | 9.3–40.0 |
| Living with parents | 24 (75.0) | 56.6–88.5 |
| Concomitant diseases and conditions | 24 (75.0) | 56.6–88.5 |
| Gastrointestinal disorders, including | 16 (50) | 31.9–68.1 |
| Biliary tract dysfunction | 16 (50) | 31.9–68.1 |
| Chronic gastritis and gastroduodenitis | 9 (28.1) | 13.8–46.8 |
| Allergic disorders | 5 (15.6) | 5.3–32.8 |
| Nervous system disorders | 1 (3.1) | 0.08–16.2 |
| Neoplasms | 3 (9.4) | 1.9–25.0 |
| Endocrine and metabolic disorders, including | 3 (9.4) | 1.9–25.0 |
| Type 1 diabetes mellitus | 1 (3.1) | 0.08–16.2 |
| Gilbert’s syndrome | 1 (3.1) | 0.08–16.2 |
| Systemic vasculitis | 1 (3.1) | 0.08–16.2 |
| Chronic liver disease | 15 (46.9) | 29.1–65.3 |
| Minimal activity (ALT < 2 ULN) | 12 (37.5) | 21.1–56.3 |
| Low activity (ALT 2 to 5 ULN) | 2 (6.25) | 0.77–20.8 |
| Intermediate activity (ALT 5 to 10 ULN) | 1 (3.1) | 0.08–16.2 |
| HCV genotype |
| GT1a | 3 (9.4) | 1.9–25.0 |
| GT1b | 11 (34.4) | 18.6–53.2 |
| GT1a/1b | 1 (3.1) | 0.08–16.2 |
| GT3a | 8 (25.0) | 11.5–43.4 |
| GT3a/3b | 9 (28.1) | 13.8–46.8 |
| GT1, total | 15 (46.9) | 29.1–65.3 |
| GT3, total | 17 (53.1) | 34.7–70.9 |
| Viral load |
| 104 IU/mL | 11 (34.4) | 18.6–53.2 |
| 105 IU/mL | 12 (37.5) | 21.1–56.3 |
| 106 IU/mL | 8 (25.0) | 11.5–43.4 |
| 107 IU/mL | 1 (3.13) | 0.08–16.2 |
| Liver fibrosis grade by METAVIR |
| F0 | 17 (53.1) | 21.1–56.3 |
| F1 | 12 (37.5) | 21.1–56.3 |
| F2 | 3 (9.37) | 1.9–25.0 |

ALT, alanine aminotransferase; CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus

**Table 2. Changes in serum clinical chemistry parameters over time in the HCV-infected children during the follow-up**

|  |  |
| --- | --- |
| **Parameter** | **Means and standard deviation, M ± SD (n = 32)** |
| **At baseline** | **At week 4 of the treatment** | **At week 8 of the treatment** | **SVR12** |
| ALT, U/mL | 48.75 ± 54.67 | 17.47 ± 7.28\* | 13.22 ± 3.28\* | 13.54 ± 5.06\* |
| AST, U/mL | 38.83 ± 25.50 | 29.65 ± 3.56\* | 19.28 ± 3.04\* | 18.89 ± 4.89\* |
| TB, mcmol/L | 14.13 ± 11.17 | 11.08 ± 6.12 | 11.95 ± 8.53 | 14.14 ± 13.56 |
| AP, U/L | 246.38 ± 203.95 | 180.81 ± 109.43\* | 172.96 ± 95.29\* | 179.10 ± 121.01 |

ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; HCV, hepatitis C virus; SVR12, sustained viral response at 12 weeks of treatment; TB, total bilirubin

\* р < 0.05 compared to baseline values

**Table 3. Adverse events during the treatment in the children with HCV infection (n = 32)**

|  |  |  |
| --- | --- | --- |
| **Adverse event** | **Patient numbers, n (%)** | **95% CI** |
| Headache | 2 (6.25) | 0.77–20.8 |
| Fatigue | 2 (6.25) | 0.77–20.8 |
| Asthenia | – |  |
| Nausea | 1 (3.1) | 0.08–16.2 |
| Diarrhea | 1 (3.1) | 0.08–16.2 |
| Rhinitis | 5 (15.6) | 5.3–32.8 |
| Cough | 3 (9.4) | 1.9–25.0 |
| Pharyngeal pain | 4 (12.5) | 3.5–29.0 |
| Skin itching | – |  |
| Total number of patients with GLE/PIB-related symptoms | 3 (9.4) | 1.9–25.0 |
| Total number of patients with GLE/PIV-unrelated symptoms | 5 (15.6) | 5.3–32.8 |
| Total | 8 (25.0) | 11.5–43.4 |

CI, confidence interval; GLE/PIB, glecaprevir/pibrentasvir; HCV, hepatitis C virus